Royal Bank of Canada’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-6,923
| Closed | -$105K | – | 8146 |
|
|
2022
Q3 | $105K | Sell |
6,923
-3,126
| -31% | -$36.3K | ﹤0.01% | 5281 |
|
|
2022
Q2 | $75K | Buy |
10,049
+474
| +5% | +$3.34K | ﹤0.01% | 5521 |
|
|
2022
Q1 | $87K | Sell |
9,575
-5,680
| -37% | -$43.8K | ﹤0.01% | 5754 |
|
|
2021
Q4 | $106K | Buy |
15,255
+12,286
| +414% | +$129K | ﹤0.01% | 5895 |
|
|
2021
Q3 | $34K | Buy |
2,969
+1,703
| +135% | +$24.9K | ﹤0.01% | 6392 |
|
|
2021
Q2 | $20K | Sell |
1,266
-2,195
| -63% | -$37.7K | ﹤0.01% | 6580 |
|
|
2021
Q1 | $61K | Buy |
3,461
+1,077
| +45% | +$18.6K | ﹤0.01% | 5776 |
|
|
2020
Q4 | $33K | Buy |
2,384
+57
| +2% | +$689 | ﹤0.01% | 5843 |
|
|
2020
Q3 | $27K | Sell |
2,327
-135
| -5% | -$1.64K | ﹤0.01% | 5585 |
|
|
2020
Q2 | $36K | Sell |
2,462
-698
| -22% | -$10.3K | ﹤0.01% | 5365 |
|
|
2020
Q1 | $43K | Sell |
3,160
-5,040
| -61% | -$95.6K | ﹤0.01% | 5236 |
|
|
2019
Q4 | $198K | Buy |
8,200
+861
| +12% | +$17.8K | ﹤0.01% | 4646 |
|
|
2019
Q3 | $141K | Buy |
7,339
+512
| +7% | +$11.7K | ﹤0.01% | 4639 |
|
|
2019
Q2 | $201K | Sell |
6,827
-10,599
| -61% | -$408K | ﹤0.01% | 4481 |
|
|
2019
Q1 | $828K | Sell |
17,426
-937
| -5% | -$41.2K | ﹤0.01% | 3339 |
|
|
2018
Q4 | $663K | Sell |
18,363
-1,636
| -8% | -$76.8K | ﹤0.01% | 3491 |
|
|
2018
Q3 | $1.23M | Sell |
19,999
-7,928
| -28% | -$510K | ﹤0.01% | 3202 |
|
|
2018
Q2 | $1.89M | Sell |
27,927
-4,948
| -15% | -$277K | ﹤0.01% | 2774 |
|
|
2018
Q1 | $1.78M | Buy |
32,875
+2,511
| +8% | +$140K | ﹤0.01% | 2766 |
|
|
2017
Q4 | $1.81M | Sell |
30,364
-9,455
| -24% | -$573K | ﹤0.01% | 2804 |
|
|
2017
Q3 | $1.94M | Sell |
39,819
-37,643
| -49% | -$2.05M | ﹤0.01% | 2689 |
|
|
2017
Q2 | $4.07M | Sell |
77,462
-11,621
| -13% | -$541K | ﹤0.01% | 2088 |
|
|
2017
Q1 | $4.04M | Sell |
89,083
-6,176
| -6% | -$275K | ﹤0.01% | 2060 |
|
|
2016
Q4 | $3.6M | Buy |
95,259
+2,817
| +3% | +$107K | ﹤0.01% | 2168 |
|
|
2016
Q3 | $3.49M | Sell |
92,442
-7,009
| -7% | -$155K | ﹤0.01% | 2153 |
|
|
2016
Q2 | $1.75M | Sell |
99,451
-3,102
| -3% | -$50.2K | ﹤0.01% | 2653 |
|
|
2016
Q1 | $1.25M | Buy |
102,553
+6,486
| +7% | +$103K | ﹤0.01% | 2859 |
|
|
2015
Q4 | $2.34M | Buy |
96,067
+6,955
| +8% | +$162K | ﹤0.01% | 2417 |
|
|
2015
Q3 | $1.58M | Sell |
89,112
-2,684
| -3% | -$48.6K | ﹤0.01% | 2461 |
|
|
2015
Q2 | $1.62M | Sell |
91,796
-11,299
| -11% | -$207K | ﹤0.01% | 2492 |
|
|
2015
Q1 | $3.23M | Buy |
103,095
+26,787
| +35% | +$776K | ﹤0.01% | 1909 |
|
|
2014
Q4 | $2.23M | Buy |
76,308
+13,652
| +22% | +$346K | ﹤0.01% | 2243 |
|
|
2014
Q3 | $1.3M | Buy |
62,656
+56,481
| +915% | +$1.11M | ﹤0.01% | 2642 |
|
|
2014
Q2 | $153K | Sell |
6,175
-36,552
| -86% | -$633K | ﹤0.01% | 4334 |
|
|
2014
Q1 | $905K | Buy |
42,727
+42,452
| +15,437% | +$858K | ﹤0.01% | 2853 |
|
|
2013
Q4 | $5K | Buy |
+275
| New | +$3.58K | ﹤0.01% | 5614 |
|
Royal Bank of Canada's AERI Position: Q4 2022 in Review
Royal Bank of Canada sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 6,923 shares — an estimated $105K sold.
Royal Bank of Canada first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $4.07M in Q2 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Royal Bank of Canada reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Royal Bank of Canada sold 6,923 Aerie Pharmaceuticals shares in Q4 2022, an estimated $105K.
- Royal Bank of Canada first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
- Royal Bank of Canada's Aerie Pharmaceuticals position peaked at $4.07M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.